Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.42 |
| ▸ | CYP51A1 | Q16850 | 6/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1527256 | 0.84 | AOC3 (0.51) | SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL5069152 | 0.84 | AOC3 (0.51) | SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL5069157 | 0.84 | AOC3 (0.51) | SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL5065719 | 0.82 | CYP51A1 (0.39) | SMN1; SMN2LMNAL3MBTL1ADRB3ADRB1 | |
| SCHEMBL4688450 | 0.77 | CNR1 (0.44) | KCNA5TBXAS1 | |
| SCHEMBL16115271 | 0.77 | SLC6A2 (0.60) | CYP51A1 | |
| SCHEMBL4540654 | 0.76 | KCNA5 (0.64) | KCNA5 | |
| SCHEMBL5065739 | 0.76 | KYNU (0.50) | LMNAADRB3ADRB1 | |
| SCHEMBL6319993 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAL3MBTL1ADRB3CYP51A1 | |
| SCHEMBL8647625 | 0.75 | TAAR1 (0.42) | SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | SMN1; SMN2 3299/4885LMNA 3066/4885L3MBTL1 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.